Cytek Biosciences, Inc. CTKB
Biotechnology: Laboratory Analytical Instruments · IPO 2021 · data as of November 13, 2026
Cytek Biosciences, Inc. (CTKB) is a industrial company listed in the US with a market value of about $764M. In the twelve months to September 30, 2026 it had revenue of $208M and net income of -$81M, a net margin of -39.1%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 17% a year, a 5-year average ROIC of -3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 84% below the current price.
About Cytek Biosciences
Cytek Biosciences is listed in the US and classified in biotechnology: laboratory analytical instruments, IPO year 2021. Revenue went from $93M in 2020 to $201M in 2025, growth of about 16.8% a year. It was profitable in 3 of the last 6 years in our data. Its share count fell by 8% over three years (buybacks). It spends 18% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $208M | $201M | $200M | $193M | $164M | $128M | $93M |
| Net income | -$81M | -$67M | -$6M | -$12M | $2M | $3M | $19M |
| Free cash flow | -$13M | -$9M | $22M | $633000 | -$22M | $266000 | $14M |
| EPS (diluted) | $-0.63 | $-0.52 | $-0.05 | $-0.09 | $0.02 | $0.00 | $0.10 |
| Net margin | -39.1% | -33.0% | -3.0% | -6.3% | 1.5% | 2.4% | 20.9% |
| ROIC | — | -8.9% | -4.0% | -5.3% | -0.3% | 1.1% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $6.50, 11% above the current price; targets range from $5.00 to $7.50; the consensus rating is “Buy”; expected EPS is $-0.29 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Cytek Biosciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 84% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Cytek Biosciences pay a dividend?
Not currently.
Is Cytek Biosciences a good stock to buy?
We do not give buy or sell advice. Cytek Biosciences scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.